Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,221 to 1,240 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spinal Muscular Atrophy: Diagnosis, Incidence, and Newborn Screening in Japan. | Int J Neonatal Screen | 2021 | 34287247 | PubTator, text mining | PubMed |
| Newborn Screening for Severe Combined Immunodeficiency Using the Multiple of the Median Values of T-Cell Receptor Excision Circles. | Int J Neonatal Screen | 2021 | 34287245 | PubTator, text mining | PubMed |
| Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). | Genet Med | 2021 | 34285390 | PubTator, text mining | PubMed |
| Recognition of single-stranded nucleic acids by small-molecule splicing modulators. | Nucleic Acids Res | 2021 | 34283224 | PubTator, text mining | PubMed |
| Local Translation in Nervous System Pathologies. | Front Integr Neurosci | 2021 | 34276318 | PubTator, text mining | PubMed |
| Gene therapy for spinal muscular atrophy: the Qatari experience. | Gene Ther | 2021 | 34276047 | PubTator, text mining | PubMed |
| Motor unit number index: A potential electrophysiological biomarker for pediatric spinal muscular atrophy. | Muscle Nerve | 2021 | 34255873 | PubTator, text mining | PubMed |
| Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy. | J Pediatr Pharmacol Ther | 2021 | 34239394 | PubTator, text mining | PubMed |
| Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. | JCI Insight | 2021 | 34236053 | PubTator, text mining | PubMed |
| Selecting disease-modifying medications in 5q spinal muscular atrophy. | Muscle Nerve | 2021 | 34231920 | PubTator, text mining | PubMed |
| Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. | Pharmacoeconomics | 2021 | 34231135 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy autophagy profile is tissue-dependent: differential regulation between muscle and motoneurons. | Acta Neuropathol Commun | 2021 | 34217376 | PubTator, text mining | PubMed |
| Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases. | Evid Based Complement Alternat Med | 2021 | 34211575 | PubTator, text mining | PubMed |
| Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases. | Pharmaceuticals (Basel) | 2021 | 34204831 | PubTator, text mining | PubMed |
| Landscape of Spinal Muscular Atrophy Newborn Screening in the United States: 2018-2021. | Int J Neonatal Screen | 2021 | 34202531 | PubTator, text mining | PubMed |
| Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects. | Pharmaceutics | 2021 | 34200425 | PubTator, text mining | PubMed |
| Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. | Muscle Nerve | 2021 | 34196026 | PubTator, text mining | PubMed |
| Axonal Transport and Local Translation of mRNA in Neurodegenerative Diseases. | Front Mol Neurosci | 2021 | 34194300 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency. | Semin Pediatr Neurol | 2021 | 34183144 | PubTator, text mining | PubMed |
| Assembly of higher-order SMN oligomers is essential for metazoan viability and requires an exposed structural motif present in the YG zipper dimer. | Nucleic Acids Res | 2021 | 34181727 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=62